NOVOCURE LIMITED

(NVCR)
  Report
Delayed Nasdaq  -  04:00 2022-07-01 pm EDT
73.30 USD   +5.47%
07/01Novocure to Report Second Quarter 2022 Financial Results
BU
06/24NOVOCURE LIMITED(NASDAQGS : NVCR) added to Russell 2500 Index
CI
06/24NOVOCURE LIMITED(NASDAQGS : NVCR) added to Russell 2500 Growth Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Evercore ISI Adjusts Price Target for NovoCure to $82 From $62, Maintains In-Line Rating

04/04/2022 | 03:11pm EDT


© MT Newswires 2022
All news about NOVOCURE LIMITED
07/01Novocure to Report Second Quarter 2022 Financial Results
BU
06/24NOVOCURE LIMITED(NASDAQGS : NVCR) added to Russell 2500 Index
CI
06/24NOVOCURE LIMITED(NASDAQGS : NVCR) added to Russell 2500 Growth Index
CI
06/21NovoCure Enrolls First Patient in Study of Tumor Treating Fields, Keytruda Combination ..
MT
06/21Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields T..
BU
06/21Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields T..
CI
06/10NOVOCURE LTD : Change in Directors or Principal Officers, Amendments to Articles of Inc. o..
AQ
06/06HC Wainwright Initiates NovoCure at Buy, Sets Price Target at $115
MT
06/03Novocure Falls 5%, Zai Lab Rises 8%; Companies Report Study Results
DJ
06/03Zai Lab, Novocure's Phase 2 Study of Gastric Cancer Combination Therapy Meets Primary E..
MT
More news
Analyst Recommendations on NOVOCURE LIMITED
More recommendations
Financials (USD)
Sales 2022 552 M - -
Net income 2022 -62,6 M - -
Net Debt 2022 293 M - -
P/E ratio 2022 -126x
Yield 2022 -
Capitalization 7 666 M 7 666 M -
EV / Sales 2022 14,4x
EV / Sales 2023 13,4x
Nbr of Employees 1 167
Free-Float 86,7%
Chart NOVOCURE LIMITED
Duration : Period :
NovoCure Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVOCURE LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 73,30 $
Average target price 101,44 $
Spread / Average Target 38,4%
EPS Revisions
Managers and Directors
Asaf Danziger Chief Executive Officer & Director
Ashley Cordova Chief Financial Officer
William F. Doyle Executive Chairman
Uri Weinberg Chief Science Officer
Ely Benaim Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVOCURE LIMITED-2.37%7 666
MASIMO CORPORATION-55.37%7 543
SHOCKWAVE MEDICAL, INC.11.38%7 109
GETINGE AB-39.00%6 347
IRAY TECHNOLOGY COMPANY LIMITED-9.21%4 884
PENUMBRA, INC.-56.25%4 736